Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02133196 · ClinicalTrials.gov registry record · Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

A Phase 2 study of Squamous Cell Carcinoma and Adenocarcinoma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 2
Development phase
85
Enrollment target
1
Study location

NCT02133196: Recruiting Phase 2 study of Squamous Cell Carcinoma and Adenocarcinoma, sponsored by National Cancer Institute (NCI).

NCT02133196 is a Phase 2 study of Squamous Cell Carcinoma and Adenocarcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 85 participants, below the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02133196, a Phase 2 study of Squamous Cell Carcinoma and Adenocarcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 2
Development phase
85 participants
Enrollment target
1
Study location

Study Summary

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 100 patients. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause non-small cell lung cancer (NSCLC) tumors to shrink and to see if this treatment is safe. Eligibility: \- Adults age 18-72 with NSCLC who have a tumor that can be safely removed. Design: * Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed * Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. * Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. {Leukapheresis is a common procedure, which removes only the white blood cells from the patient.} * Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits take up to 2 days. ...

Primary Outcome

Percentage of patients who have a clinical response to treatment (objective tumor regression)

Conditions Studied

Squamous Cell Carcinoma Adenocarcinoma Advanced Non-Small-Cell Lung Cancer Adenosquamous Carcinoma Advanced NSCLC

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG Aldesleukin
  • BIOLOGICAL Young TIL

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2014-10-23
Est. Completion 2027-10-23
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What NCT02133196 shows while recruiting

NCT02133196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (17% lower).

The record links to 5 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT02133196 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02133196 about?

NCT02133196 is a clinical study titled "T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer". Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we...

What is the current status of trial NCT02133196?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2014-10-23. Estimated completion is 2027-10-23.

What conditions does trial NCT02133196 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Adenocarcinoma, Advanced Non-Small-Cell Lung Cancer, Adenosquamous Carcinoma, Advanced NSCLC.

What interventions are being tested in trial NCT02133196?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Aldesleukin (DRUG), Young TIL (BIOLOGICAL).

Who is sponsoring clinical trial NCT02133196?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02133196 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02133196's enrollment target sits among peer trials

85 14th of 47 higher than 34 of 47 other Squamous Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

  • NCT03896529 · 85 participants · NA

    Neurobiological Mechanisms of Aging and Stress on Prospective Navigation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT02133196

Source: ClinicalTrials.gov NCT02133196, the US trial registry maintained by the National Library of Medicine. NCT02133196 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.